1272 related articles for article (PubMed ID: 29020404)
1. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.
van Duin D; Lok JJ; Earley M; Cober E; Richter SS; Perez F; Salata RA; Kalayjian RC; Watkins RR; Doi Y; Kaye KS; Fowler VG; Paterson DL; Bonomo RA; Evans S;
Clin Infect Dis; 2018 Jan; 66(2):163-171. PubMed ID: 29020404
[TBL] [Abstract][Full Text] [Related]
2. Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.
Shields RK; Potoski BA; Haidar G; Hao B; Doi Y; Chen L; Press EG; Kreiswirth BN; Clancy CJ; Nguyen MH
Clin Infect Dis; 2016 Dec; 63(12):1615-1618. PubMed ID: 27624958
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam.
De la Calle C; Rodríguez O; Morata L; Marco F; Cardozo C; García-Vidal C; Río AD; Feher C; Pellicé M; Puerta-Alcalde P; Mensa J; Soriano A; Martínez JA
Int J Antimicrob Agents; 2019 Apr; 53(4):520-524. PubMed ID: 30471403
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae.
Sousa A; Pérez-Rodríguez MT; Soto A; Rodríguez L; Pérez-Landeiro A; Martínez-Lamas L; Nodar A; Crespo M
J Antimicrob Chemother; 2018 Nov; 73(11):3170-3175. PubMed ID: 30099490
[TBL] [Abstract][Full Text] [Related]
5. Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections.
King M; Heil E; Kuriakose S; Bias T; Huang V; El-Beyrouty C; McCoy D; Hiles J; Richards L; Gardner J; Harrington N; Biason K; Gallagher JC
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483952
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.
Santevecchi BA; Smith TT; MacVane SH
Int J Antimicrob Agents; 2018 Apr; 51(4):629-635. PubMed ID: 29408227
[TBL] [Abstract][Full Text] [Related]
7. Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation.
Krapp F; Grant JL; Sutton SH; Ozer EA; Barr VO
Int J Antimicrob Agents; 2017 Jun; 49(6):770-773. PubMed ID: 28389354
[TBL] [Abstract][Full Text] [Related]
8. Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant
Ackley R; Roshdy D; Meredith J; Minor S; Anderson WE; Capraro GA; Polk C
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094128
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae.
Alraddadi BM; Saeedi M; Qutub M; Alshukairi A; Hassanien A; Wali G
BMC Infect Dis; 2019 Sep; 19(1):772. PubMed ID: 31484510
[TBL] [Abstract][Full Text] [Related]
10. Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations.
Pogue JM; Bonomo RA; Kaye KS
Clin Infect Dis; 2019 Jan; 68(3):519-524. PubMed ID: 30020449
[TBL] [Abstract][Full Text] [Related]
11. Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia.
Shields RK; Nguyen MH; Chen L; Press EG; Potoski BA; Marini RV; Doi Y; Kreiswirth BN; Clancy CJ
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559250
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
[TBL] [Abstract][Full Text] [Related]
13. Colistin Does Not Potentiate Ceftazidime-Avibactam Killing of Carbapenem-Resistant Enterobacteriaceae In Vitro or Suppress Emergence of Ceftazidime-Avibactam Resistance.
Shields RK; Nguyen MH; Hao B; Kline EG; Clancy CJ
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29891598
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Persistently Neutropenic Rabbits.
Petraitiene R; Petraitis V; Kavaliauskas P; Maung BBW; Khan F; Naing E; Aung T; Zigmantaite V; Grigaleviciute R; Kucinskas A; Stakauskas R; Georgiades BN; Mazur CA; Hayden JA; Satlin MJ; Walsh TJ
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015048
[No Abstract] [Full Text] [Related]
15. Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae.
Tumbarello M; Trecarichi EM; Corona A; De Rosa FG; Bassetti M; Mussini C; Menichetti F; Viscoli C; Campoli C; Venditti M; De Gasperi A; Mularoni A; Tascini C; Parruti G; Pallotto C; Sica S; Concia E; Cultrera R; De Pascale G; Capone A; Antinori S; Corcione S; Righi E; Losito AR; Digaetano M; Amadori F; Giacobbe DR; Ceccarelli G; Mazza E; Raffaelli F; Spanu T; Cauda R; Viale P
Clin Infect Dis; 2019 Jan; 68(3):355-364. PubMed ID: 29893802
[TBL] [Abstract][Full Text] [Related]
16. Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections.
Shirley M
Drugs; 2018 Apr; 78(6):675-692. PubMed ID: 29671219
[TBL] [Abstract][Full Text] [Related]
17. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
Sharma R; Park TE; Moy S
Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
[TBL] [Abstract][Full Text] [Related]
18. Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme.
Stone GG; Newell P; Gasink LB; Broadhurst H; Wardman A; Yates K; Chen Z; Song J; Chow JW
J Antimicrob Chemother; 2018 Sep; 73(9):2519-2523. PubMed ID: 29912399
[TBL] [Abstract][Full Text] [Related]
19. Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections.
Shields RK; Nguyen MH; Chen L; Press EG; Kreiswirth BN; Clancy CJ
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29507064
[TBL] [Abstract][Full Text] [Related]
20. Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae.
Jayol A; Nordmann P; Poirel L; Dubois V
J Antimicrob Chemother; 2018 Feb; 73(2):542-544. PubMed ID: 29165563
[No Abstract] [Full Text] [Related]
[Next] [New Search]